



**THE FOUNDATION
FOR SECURE
MARKETS®**

#52518

Date: June 01, 2023

Subject: TCR2 Therapeutics Inc. - Contract Adjustment
Option Symbol: 06/01/2023 - TCRR remains TCRR
06/02/2023 - TCRR becomes ADAP1
Date: 06/01/2023

Contract Adjustment

Date: June 1, 2023

Option Symbol: 06/01/2023 - TCRR remains TCRR (with adjusted deliverable as described below)
06/02/2023 - TCRR changes to ADAP1

Strike Divisor: 1

Contracts Multiplier: 1

New Multiplier: 100 (e.g., a premium of 1.50 yields \$150; a strike of 2.50 yields \$250.00)

New Deliverable Per Contract: 151 Adaptimmune Therapeutics plc (ADAP) American Depositary Shares

CUSIP: ADAP: 00653A107

Pricing

The underlying price for ADAP1 will be determined as follow:

$$\text{ADAP1} = 1.51 \text{ (ADAP)}$$

Background

On May 31, 2023, Shareholders of TCR2 Therapeutics Inc. (TCRR) voted concerning the proposed merger with Adaptimmune Therapeutics plc (ADAP). The merger was approved and subsequently consummated before the open on June 1, 2023. As a result, each existing TCRR Common Share will be converted into the

right to receive 1.5117 ADAP American Depositary Shares. Fractional ADAP shares will be rounded down to the nearest whole share.

Disclaimer

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, please email the Investor Education team at options@theocc.com. Clearing Member Firms of OCC may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email memberservices@theocc.com.